Annals of Hematology

, Volume 98, Issue 1, pp 169–173 | Cite as

MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type

  • Anahita Nosrati
  • Ahmad MonabatiEmail author
  • Alireza Sadeghipour
  • Fatemeh Radmanesh
  • Akbar Safaei
  • Sajjadeh Movahedinia
Original Article


Primary central nervous system lymphoma (PCNSL) is a rare specific subtype of non-Hodgkin lymphoma limited to the brain, leptomeninges, spinal cord, or eyes without any systemic presentation and relapse which mostly takes place in CNS. In more than 95% of patients, it is of diffuse large B cell lymphoma (DLBCL) type. Categorizing PCNSL to germinal center cell like or activated B cell like, as we usually do for DLBCL NOS, may not be applicable for predicting outcome. Possible prognostic significance of MYC, BCL2, and/or BCL6 rearrangements may be important given what we know about their impact in systemic DLBCL, but we have limited knowledge about the status of double or triple hit molecular changes in PCNSL. Here, we have investigated prevalence of these molecular alterations in PCNSL. Two independent tissue microarrays constructed from 78 formalin-fixed paraffin-embedded blocks of confirmed PCNSL were tested for rearrangement of MYC, BCL2, and BCL6 by interphase fluorescent in situ hybridization (FISH) using break apart dual color probes. BCL6 translocation was detected in 15 (12%) cases. Translocation involving MYC and BCL2 was identified in 3 cases (3.8%) and 1 case (1.3%) respectively. One double hit lymphoma was discovered with both MYC/BCL2 translocation (1.3%). To the best of our knowledge, few organized studies have been conducted for MYC, BCL2, and/or BCL6 rearrangement in PCNSL. This study is evaluating large number of PCNSL. Double or triple hit events which are rarely seen in PCNSL.


Primary central nervous system lymphoma MYC BCL2 BCL6 Rearrangement 


Authors’ contribution

Anahita Nosrati participated in assessing FISH cases, drafting, proofreading, and finally writing of the manuscript. Ahmad Monabati and Akbar Safaei both participated in final assessing of all FISH cases and are essentially responsible for writing of manuscript and submission. Alireza Sadeghipour participated in introducing and preparing the clinical data of patients. Fatemeh Radmanesh and Sajjadeh Movahedinia, both participated in introducing clinical data of patients. All authors critically revised and approved the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Yang X-L, Liu Y-B (2017) Advances in pathobiology of primary central nervous system lymphoma. Chin Med J 130(16):1973–1979. CrossRefGoogle Scholar
  2. 2.
    Provencher S, Ferlay C, Alaoui-Slimani K, Devidas A, Lepretre S, de Prijck B, Sebban C, de la Fouchardiere A, Chassagne-Clement C, Ketterer N (2011) Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series. Hematol Oncol 29(1):10–16. CrossRefGoogle Scholar
  3. 3.
    Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117(19):5019–5032. CrossRefGoogle Scholar
  4. 4.
    Montesinos-Rongen M, Purschke F, Küppers R, Deckert M (2014) Immunoglobulin repertoire of primary lymphomas of the central nervous system. J Neuropathol Exp Neurol 73(12):1116–1125. CrossRefGoogle Scholar
  5. 5.
    Raoux D, Duband S, Forest F, Trombert B, Chambonnière ML, Dumollard JM, Khaddage A, Gentil-Perret A, Péoc'h M (2010) Primary central nervous system lymphoma: immunohistochemical profile and prognostic significance. Neuropathology 30(3):232–240. CrossRefGoogle Scholar
  6. 6.
    Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD (2016) The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms. Blood 127(20):2375–2390. CrossRefGoogle Scholar
  7. 7.
    Li S, Seegmiller AC, Lin P, Wang XJ, Miranda RN, Bhagavathi S, Medeiros LJ (2015) B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas. Mod Pathol 28(2):208–217. CrossRefGoogle Scholar
  8. 8.
    Rosenthal A, Younes A (2017) High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev 31(2):37–42. CrossRefGoogle Scholar
  9. 9.
    Yan L-X, Liu Y-H, Luo D-L, Zhang F, Cheng Y, Luo X-L, Xu J, Cheng J, Zhuang H-G (2014) MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified. PLoS One 9(8):e104068. CrossRefGoogle Scholar
  10. 10.
    Cady FM, O’Neill BP, Law ME, Decker PA, Kurtz DM, Giannini C, Porter AB, Kurtin PJ, Johnston PB, Dogan A (2008) Del (6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol 26(29):4814–4819. CrossRefGoogle Scholar
  11. 11.
    Mrugala MM, Rubenstein JL, Ponzoni M, Batchelor TT (2009) Insights into the biology of primary central nervous system lymphoma. Curr Oncol Rep 11(1):73–80. CrossRefGoogle Scholar
  12. 12.
    Oliveira CC, Maciel-Guerra H, Kucko L, Hirama EJ, Brilhante AD, Quevedo FC, da Cunha IW, Soares FA, Niero-Melo L, dos Reis PP (2017) Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma. Diagn Pathol 12(1):3. CrossRefGoogle Scholar
  13. 13.
    Iqbal J, Greiner T, Patel K, Dave B, Smith L, Ji J, Wright G, Sanger W, Pickering D, Jain S (2007) Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 21(11):2332–2343. CrossRefGoogle Scholar
  14. 14.
    Montesinos-Rongen M, Zühlke-Jenisch R, Gesk S, Martín-Subero JI, Schaller C, Van Roost D, Wiestler OD, Deckert M, Siebert R (2002) Interphase cytogenetic analysis of lymphoma-associated chromosomal breakpoints in primary diffuse large B-cell lymphomas of the central nervous system. J Neuropathol Exp Neurol 61(10):926–933. CrossRefGoogle Scholar
  15. 15.
    Schwindt H, Akasaka T, Zühlke-Jenisch R, Hans V, Schaller C, Klapper W, Dyer MJ, Siebert R, Deckert M (2006) Chromosomal translocations fusing the BCL6 gene to different partner loci are recurrent in primary central nervous system lymphoma and may be associated with aberrant somatic hypermutation or defective class switch recombination. J Neuropathol Exp Neurol 65(8):776–782. CrossRefGoogle Scholar
  16. 16.
    Copie-Bergman C, Cuillière-Dartigues P, Baia M, Briere J, Delarue R, Canioni D, Salles G, Parrens M, Belhadj K, Fabiani B (2015) MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood 126(22):2466–2474. CrossRefGoogle Scholar
  17. 17.
    Tzankov A, Xu-Monette ZY, Gerhard M, Visco C, Dirnhofer S, Gisin N, Dybkaer K, Orazi A, Bhagat G, Richards KL (2014) Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol 27(7):958–971. CrossRefGoogle Scholar
  18. 18.
    Kojima M, Nishikii H, Takizawa J, Aoki S, Noguchi M, Chiba S, Ando K, Nakamura N (2013) MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: multicenter analysis of Japanese patients with diffuse large B-cell lymphoma. Leuk lymphoma 54(10):2149–2154. CrossRefGoogle Scholar
  19. 19.
    Brunn A, Nagel I, Montesinos-Rongen M, Klapper W, Vater I, Paulus W, Hans V, Blümcke I, Weis J, Siebert R (2013) Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC low BCL2 low subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas. Acta Neuropathol 126(4):603–605. CrossRefGoogle Scholar
  20. 20.
    Son S-M, Ha S-Y, Yoo H-Y, Oh D, Kim S-J, Kim W-S, Ko Y-H (2017) Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression. Mod Pathol 30(1):4–782. CrossRefGoogle Scholar
  21. 21.
    Izumi K, Fujita K, Fukutsuka K, Hayashida M, Akasaka T, Ohno H (2016) MYC/BCL2/BCL6 triple-hit lymphoma that presented with a suprasellar tumor and meningeal dissemination: a case report. Tenri Med Bull 19(1):24–33. CrossRefGoogle Scholar
  22. 22.
    Yin W, Zhu X, Yang H, Sun W, Wu M (2018) Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens. Zhonghua Bing Li Xue Za Zhi 47(1):32–38. Google Scholar
  23. 23.
    Montesinos-Rongen M, Brunn A, Bentink S, Basso K, Lim W, Klapper W, Schaller C, Reifenberger G, Rubenstein J, Wiestler O (2008) Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. Leukemia 22(2):400–405. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Anahita Nosrati
    • 1
  • Ahmad Monabati
    • 2
    Email author
  • Alireza Sadeghipour
    • 3
  • Fatemeh Radmanesh
    • 4
  • Akbar Safaei
    • 5
  • Sajjadeh Movahedinia
    • 6
    • 7
  1. 1.Hematopatholgy Service, Department of Pathology, School of MedicineShiraz University of Medical SciencesShirazIran
  2. 2.Hematopatholgy Service, Department of Pathology and Hematology Research Center, School of MedicineShiraz University of Medical SciencesShirazIran
  3. 3.Department of Pathology, Rasool-Akram HospitalIran University of Medical SciencesTehranIran
  4. 4.Department of PathologyShiraz University of Medical SciencesShirazIran
  5. 5.Molecular Pathology and Cytogenetics, Department of PathologyShiraz University of Medical SciencesShirazIran
  6. 6.Pathology and Stem Cell Research Center, Afzalipour Medical SchoolKerman University of Medical SciencesKermanIran
  7. 7.Oncopathology Research CenterIran University of Medical SciencesTehranIran

Personalised recommendations